Trial · NCT02221869
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Weekly Number of Cataplexy Attacks | Xyrem | 0.27 | Inter-Quartile Range -1.00 to 2.50 | number of attacks | |
| Change in Weekly Number of Cataplexy Attacks | Xyrem Placebo | 12.71 | Inter-Quartile Range 3.44 to 19.77 | number of attacks | |
| Clinical Global Impression of Change (CGIc) for Cataplexy Severity | Xyrem | -0.4 | Standard Deviation 1.12 | score on a scale | |
| Clinical Global Impression of Change (CGIc) for Cataplexy Severity | Xyrem Placebo | -1.5 | Standard Deviation 1.19 | score on a scale | |
| Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score | Xyrem | 0.0 | Inter-Quartile Range -1.0 to 2.0 | score on a scale | |
| Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score | Xyrem Placebo | 3.0 | Inter-Quartile Range 1.0 to 5.0 | score on a scale | |
| CGIc for Narcolepsy Overall | Xyrem | -0.4 | Standard Deviation 0.95 | score on a scale | |
| CGIc for Narcolepsy Overall | Xyrem Placebo | -1.4 | Standard Deviation 1.13 | score on a scale | |
| Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period | Xyrem | SF-10 Physical Summary Score | 0 | Inter-Quartile Range -2.730 to 2.500 | score on a scale |
| Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period | Xyrem Placebo | SF-10 Physical Summary Score | 0 | Inter-Quartile Range -8.420 to 2.730 | score on a scale |
| Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period | Xyrem | SF-10 Psychosocial Summary Score | 0 | Inter-Quartile Range -6.240 to 2.680 | score on a scale |
| Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period | Xyrem Placebo | SF-10 Psychosocial Summary Score | -2.670 | Inter-Quartile Range -8.020 to 2.670 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02221869/results